Latest news with #DigitalTherapeutics
Yahoo
2 days ago
- Business
- Yahoo
Quantum eMotion Expands Strategic Stake in Greybox Solutions to Capitalize on the Digital Therapeutics Surge
Montreal, Quebec--(Newsfile Corp. - June 30, 2025) - Quantum eMotion Corp. (TSXV: QNC) (OTCQB: QNCCF) (FSE: 34Q0) ("QeM" or the "Company") is pleased to announce the conversion of $350,000 in debt into equity and an additional investment of $350,000 in Greybox Solutions Inc., strengthening its position as the second-largest shareholder in the company. This strategic investment, made at an attractive valuation, reflects QeM's strong confidence in Greybox's rapid growth trajectory and unique position in the fast-evolving Remote Care Management and Digital Therapeutics (DTx) sector. Greybox's recent launch of the secure TakeCareTM platform across Quebec leading rehabilitation centers has led to strategic commercial wins, positioning the company as a rising leader in digital health with a scalable, value-based model across Canada and beyond. "Digital therapeutics are transforming how chronic diseases are managed and patient care is delivered," said Dr. Francis Bellido, CEO of Quantum eMotion. "Greybox has demonstrated the ability to innovate, scale, and attract world-class partners. We believe this is a rare and timely opportunity to strengthen our strategic alignment with a company poised for exponential growth." QeM's proprietary cybersecurity platform, Sentry-Q, underpins the TakeCareTM security architecture. Built around QeM's patented Quantum Random Number Generator (QRNG) technology and post-quantum encryption, Sentry-Q ensures data confidentiality, treatment integrity, and system reliability-core requirements for scaling DTx platforms in clinical environments. Pierre Bérubé, CEO of Greybox Solutions, commented: "We're proud to deepen our partnership with Quantum eMotion-not only as a strategic cybersecurity provider, but now also as a significant shareholder. Their Sentry-Q quantum solution plays a vital role in securing our TakeCareTM platform as we expand across healthcare networks. Welcoming QeM to our cap table reinforces a shared vision: that the future of digital therapeutics must be built on trusted, quantum-safe infrastructure. The appointment of Francis Bellido to the Board of Directors of Greybox will also bring a unique experience-based expertise and direct access to a large network in the healthcare industry." As the DTx market is projected to grow at over 20% CAGR globally, QeM's investment not only reinforces its role as a cybersecurity leader in healthcare but also unlocks strategic exposure to a transformative sector reshaping global healthcare delivery About Greybox Solutions Greybox Solutions is a growing Montreal-based health technology company specializing in innovative software development to improve patients' lives. Its mission is to find digital transformation solutions to address healthcare system challenges and reduce the burden of managing chronic illnesses. Greybox distributes its digital health platform, TakeCareTM to redefine the relationship between patients and their healthcare team. About QeM The Company aims to address the growing demand for affordable hardware and software security for connected devices. QeM has become a pioneering force in classical and quantum cybersecurity solutions thanks to its patented Quantum Random Number Generator, a security solution that exploits the built-in unpredictability of quantum mechanics and promises to provide enhanced protection for high-value assets and critical systems. The Company intends to target highly valued Financial Services, Healthcare, Blockchain Applications, Cloud-Based IT Security Infrastructure, Classified Government Networks and Communication Systems, Secure Device Keying (IOT, Automotive, Consumer Electronics) and Quantum Cryptography. For further information, please visit our website at or contact: Francis Bellido, Chief Executive OfficerTel: 514.956.2525Email: info@ Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain forward-looking statements that are subject to known and unknown risks and uncertainties that could cause actual results to vary materially from targeted results. Such risks and uncertainties include those described in the Corporation's periodic reports, including the annual report, or in the filings made by Quantum from time to time with securities regulatory authorities. To view the source version of this press release, please visit
Yahoo
02-06-2025
- Business
- Yahoo
Addiction Disorders Drugs Market Analysis and Forecast to 2030: A $39.5 Billion Opportunity Led by Pfizer, Johnson & Johnson, and Indivior
Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Addiction Disorders Drugs Market by Indication, Product Type, Route of Administration, Dosage Form, Distribution Channel, End User - Global Forecast to 2030" report has been added to Addiction Disorders Drugs Market grew from USD 27.08 billion in 2024 to USD 28.89 billion in 2025. It is expected to continue growing at a CAGR of 6.48%, reaching USD 39.49 billion by the past decade, the addiction therapeutics landscape has undergone profound transformation, propelled by breakthroughs in neuroscience and a heightened emphasis on personalized medicine. Digital therapeutics and telehealth solutions have augmented traditional pharmacotherapy, facilitating patient adherence and extending the reach of evidence-based care. Concurrently, the approval of novel opioid antagonists and long-acting formulations has redefined maintenance strategies, enabling clinicians to tailor regimens with greater these advancements, societal attitudes toward addiction are shifting, reducing stigma and encouraging earlier intervention. Collaborations between payers and providers are driving value-based payment models, incentivizing outcomes rather than volume. Moreover, regulatory agencies are streamlining approval pathways for therapies targeting high-unmet-need indications, accelerating time to market. These transformative shifts underscore a broader trend toward integrated, patient-centric frameworks that prioritize holistic recovery over symptom the Ripple Effects of 2025 US Tariff Policies on Drug Supply ChainsIn 2025, the introduction of new United States tariffs on active pharmaceutical ingredients and drug imports has generated ripple effects across the supply chain. Manufacturers dependent on overseas raw materials have confronted increased production costs, prompting adjustments in pricing strategies and contract negotiations. These cost pressures have been most pronounced for generics and off-patent formulations, where margins are inherently mitigate the impact, several stakeholders have diversified supplier networks, exploring domestic sourcing and vertical integration initiatives. Some companies have accelerated innovation pipelines to offset higher input costs through premium product launches. Meanwhile, payers and providers are recalibrating formularies to balance budgetary constraints with clinical efficacy, favoring therapies that demonstrate robust real-world outcomes. As the market adapts to this new tariff environment, agility and supply chain resilience have emerged as critical differentiators for industry Regional Dynamics Across the Americas, EMEA, and Asia-PacificRegional analysis reveals distinct market dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, high healthcare expenditure coupled with well-established regulatory frameworks fosters rapid uptake of innovative therapies, particularly in opioid and alcohol dependence. The convergence of public and private payer systems has also facilitated broad access initiatives, driving prescription volume Europe, Middle East and Africa, heterogeneity in healthcare infrastructure and reimbursement policies yields varied adoption rates. Western European markets emphasize evidence-based formulary inclusion and tend to favor branded medications, whereas emerging economies in the Middle East and Africa show heightened demand for cost-effective generic solutions. Collaborative agreements between local authorities and multinational corporations are instrumental in expanding treatment Asia-Pacific region is characterized by escalating investment in mental health programs and an accelerating shift toward outpatient care models. Nations such as Japan and Australia are pioneering long-acting injectable therapies, while Southeast Asian countries prioritize scalable, low-cost interventions. Regulatory reforms aimed at streamlining clinical trial processes are attracting significant R&D interest, positioning the region as a key growth Leading Stakeholders Steering Innovation and Market GrowthKey players are deploying multifaceted strategies to consolidate their market positions and advance therapeutic frontiers. Leading pharmaceutical companies have fortified their pipelines through acquisitions of biotech innovators specializing in novel receptor targets and long-acting delivery platforms. Strategic alliances are enabling the co-development of combination therapies that integrate pharmacological agents with digital adherence manufacturers are leveraging scale efficiencies to penetrate value-driven markets, while niche biotech firms concentrate on underserved indications and precision medicine approaches. Contract research organizations and specialty pharmacies have also emerged as vital partners, delivering integrated services that streamline patient onboarding and support adherence monitoring. The competitive landscape continues to evolve as emerging entrants pursue orphan drug designations and expedited approval pathways, challenging incumbents to maintain agility and clinical Pathways for Industry Leaders to Navigate Future ChallengesIndustry leaders should prioritize portfolio diversification by balancing established therapies with novel modalities that address unmet needs. Investment in real-world evidence generation will strengthen payer negotiations and support value-based contracting. Cultivating partnerships with digital health providers can amplify patient engagement and adherence metrics, enhancing clinical and economic chain resilience must be reinforced through dual sourcing strategies and advanced inventory management systems to mitigate tariff and geopolitical risks. Organizations are advised to explore regional manufacturing hubs to reduce import dependencies and shorten lead times. Engaging with regulatory bodies to shape policy frameworks will facilitate faster approval pathways and market access for innovative adopting patient-centric service models that integrate pharmacotherapy with psychosocial support will differentiate offerings in a crowded marketplace. Embedding predictive analytics into care delivery can anticipate relapse risks and tailor interventions, ensuring sustained patient recovery and long-term market Segmentation & CoverageThis research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations: Indication Alcohol Dependence Acamprosate Disulfiram Naltrexone Opioid Dependence Buprenorphine Methadone Naltrexone Smoking Cessation Bupropion Nicotine Replacement Therapy Gum Inhaler Lozenge Patch Varenicline Stimulant Dependence Off Label Drugs Research Drugs Product Type Branded Generic Route of Administration Injectable Intramuscular Intravenous Oral Sublingual Film Tablet Transdermal Patch Dosage Form Capsule Film Injectable Solution Patch Tablet Distribution Channel Hospital Pharmacy Online Pharmacy Retail Pharmacy End User Clinics Homecare Settings Hospitals This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions: Americas United States California Texas New York Florida Illinois Pennsylvania Ohio Canada Mexico Brazil Argentina Europe, Middle East & Africa United Kingdom Germany France Russia Italy Spain United Arab Emirates Saudi Arabia South Africa Denmark Netherlands Qatar Finland Sweden Nigeria Egypt Turkey Israel Norway Poland Switzerland Asia-Pacific China India Japan Australia South Korea Indonesia Thailand Philippines Malaysia Singapore Vietnam Taiwan The companies profiled in this Addiction Disorders Drugs market report include: Pfizer Inc. Johnson & Johnson Indivior plc Alkermes plc Camurus AB Orexo AB BioDelivery Sciences International, Inc. Titan Pharmaceuticals, Inc. Mallinckrodt plc Teva Pharmaceutical Industries Ltd. Key Attributes Report Attribute Details No. of Pages 196 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $28.89 Billion Forecasted Market Value (USD) by 2030 $39.49 Billion Compound Annual Growth Rate 6.4% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
